Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4062710 | 0.70 | — | — | |
| SCHEMBL157261 | 0.70 | MPO (0.33) | MPO | |
| SCHEMBL11805243 | 0.66 | MPO (0.33) | MPO | |
| SCHEMBL134491 | 0.65 | MPO (0.31) | MPO | |
| SCHEMBL3801963 | 0.62 | MPO (0.36) | MPO | |
| SCHEMBL545834 | 0.62 | MPO (0.33) | MPO | |
| SCHEMBL7452613 | 0.62 | — | — | |
| SCHEMBL7456782 | 0.62 | — | — | |
| SCHEMBL7617970 | 0.60 | MPO (0.41) | MPO | |
| SCHEMBL4280534 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10036066-B2 | In situ hybridization detection method | DAKO DENMARK A/S (DK) | 2018-07-31 | — | — | US | claimed |
| US-20160273035-A1 | IN SITU HYBRIDIZATION DETECTION METHOD | DAKO DENMARK A/S (DK) | 2016-09-22 | — | — | US | claimed |
| US-9017992-B2 | In situ hybridization detection method | DAKO DENMARK A/S (DK) | 2015-04-28 | — | — | US | claimed |
| EP-1490368-B1 | 2,2-BIS(HYDROXYMETHYL)CYCLOPROPYLIDENEMETHYL - PURINES AND -PYRIMIDINES AS ANTIVIRAL AGENTS | UNIV WAYNE STATE (US) | 2011-08-03 | — | — | EP | claimed |
| US-20110177500-A1 | IMMUNOHISTOCHEMISTRY DETECTION METHOD | DAKO DENMARK AS (DK) | 2011-07-21 | — | — | US | claimed |
| JP-4726630-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| US-7851454-B2 | Short immunomodulatory oligonucleotides | Idera Pharmaceutials, Inc. (US) | 2010-12-14 | — | — | US | claimed |
| US-7851453-B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | IDERA PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | claimed |
| US-20100221705-A1 | IN SITU HYBRIDIZATION DETECTION METHOD | DAKO DENMARK APS (DK) | 2010-09-02 | — | — | US | claimed |
| US-20090010938-A1 | SHORT IMMUNOMODULATORY OLIGONUCLEOTIDES | IDERA PHARMACEUTICALS, INC. | 2009-01-08 | — | — | US | claimed |
| US-20050113393-A1 | 2,2-bis-(hydroxymethyl)cyclopropylidenemethyl-purines and pyrmindines as antiviral agents | WAYNE STATE UNIVERSITY (US) | 2005-05-26 | — | — | US | claimed |
| EP-1490368-A2 | 2,2-BIS(HYDROXYMETHYL)CYCLOPROPYLIDENEMETHYL - PURINES AND -PYRIMIDINES AS ANTIVIRAL AGENTS | Wayne State University (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040198685-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | HYBRIDON, INC. | 2004-10-07 | — | — | US | claimed |
| WO-2004071468-A2 | SHORT IMMUNOMODULATORY OLIGONUCLEOTIDES | HYBRIDON INC. (US) | 2004-08-26 | — | — | WO | claimed |
| US-20040156825-A1 | Short immunomodulatory oligonucleotides | HYBRIDON, INC. | 2004-08-12 | — | — | US | claimed |
| WO-2004064782-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES | HYBRIDON, INC. (US) | 2004-08-05 | — | — | WO | claimed |
| WO-2003104440-A2 | 2,2-BIS(HYDROXYMETHYL)CYCLOPROPYLIDENEMETHYL - PURINES AND -PYRIMIDINES AS ANTIVIRAL AGENTS | WAYNE STATE UNIVERSITY (US) | 2003-12-18 | — | — | WO | claimed |
| CN-1117870-C | Method for producing nucleoside-5' -phosphate ester | AJINOMOTO KK (JP) | 2003-08-13 | — | — | CN | claimed |
| US-5126439-A | Complementary purines and pyrimidines | TEMPLE UNIVERSITY (US) | 1992-06-30 | — | — | US | claimed |
| WO-1991006645-A1 | PROCESS FOR MUTAGENESIS OF DOUBLE-STRAND CIRCULAR DNA | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1991-05-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040156825-A1 | Short immunomodulatory oligonucleotides | TLR3, CD47, TLR9 | MPO 908/4885 |
| US-20040198685-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | NT5C2, ENTPD5, TLR5 | MPO 3344/4885 |
| US-20050113393-A1 | 2,2-bis-(hydroxymethyl)cyclopropylidenemethyl-purines and pyrmindines as antiviral agents | TPMT, HPRT1, MTAP | MPO 2332/4885 |
| US-20090010938-A1 | SHORT IMMUNOMODULATORY OLIGONUCLEOTIDES | TLR3, CD47, TLR9 | MPO 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.